Molecular characterization of XABCLs. (A) Gene mutations in 25 XABCLs and the matched NSCLC tumors from which the XABCLs were derived. Only samples with mutations shown in the co-oncoplot were presented in the graph. Detailed mutation information for 25 pairs of samples is shown in supplemental Table 2. (B) RNA transcripts of type I and type II EBV detected in RNA-seq data of 15 XABCLs. LMP1 and EBNA2 were detected in all 15 samples, suggesting that XABCLs have type II or type III latency of EBV infection.